Transkaryotic Therapies About
Transkaryotic Therapies Transkaryotic Therapies, Inc. (TKT) is
a biopharmaceutical company whose major focus is on developing products for the
treatment of rare diseases. The company markets one product, Replagal™,
for the treatment of Fabry disease in the European Union and other countries,
and is developing products for Hunter syndrome and Gaucher disease. In
addition to the company's focus in the area of rare diseases, TKT is preparing
to commercialize its Gene-Activated erythropoietin product, Dynepo, in
Europe, which is approved for commercial sale. Replagal™ (agalsidase alfa) Replagal enzyme replacement
therapy is indicated for use in treating Fabry disease. Dynepo (epoetin
delta) Dynepo, Gene-Activated erythropoietin, is indicated for use in treating
anemia associated with kidney disease. I2S -- Hunter syndrome GA-GCB
--Gaucher disease More About Transkaryotic
Therapies
Key
Statistics for Transkaryotic